Iterum Therapeutics plc
ITRM
$1.01
-$0.01-0.98%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.04% | 25.49% | -2.89% | 2.31% | 4.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.80% | -67.89% | -70.71% | -63.26% | -27.75% |
| Operating Income | 39.80% | 67.89% | 70.71% | 63.26% | 27.75% |
| Income Before Tax | 31.50% | 46.34% | -60.33% | 58.81% | 27.78% |
| Income Tax Expenses | 25.00% | -82.39% | -15.53% | -83.42% | -60.98% |
| Earnings from Continuing Operations | 31.12% | 46.76% | -57.18% | 59.18% | 28.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.12% | 46.76% | -57.18% | 59.18% | 28.19% |
| EBIT | 39.80% | 67.89% | 70.71% | 63.26% | 27.75% |
| EBITDA | 45.40% | 68.98% | 69.97% | 61.79% | 23.94% |
| EPS Basic | 68.79% | 73.71% | -2.25% | 68.08% | 41.00% |
| Normalized Basic EPS | 68.98% | 73.49% | -4.32% | 67.79% | 40.66% |
| EPS Diluted | 68.79% | 73.52% | -2.25% | 68.08% | 41.00% |
| Normalized Diluted EPS | 68.98% | 73.49% | -4.32% | 67.79% | 40.66% |
| Average Basic Shares Outstanding | 120.70% | 102.48% | 53.72% | 27.89% | 21.69% |
| Average Diluted Shares Outstanding | 120.70% | 102.48% | 53.72% | 27.89% | 21.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |